| Year |
Citation |
Score |
| 2023 |
Gao Y, Jiang B, Kim H, Berberich MJ, Che J, Donovan KA, Hatcher JM, Huerta F, Kwiatkowski NP, Liu Y, Liuni PP, Metivier RJ, Murali VK, Nowak RP, Zhang T, et al. Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry. PMID 37036171 DOI: 10.1021/acs.jmedchem.2c01864 |
0.328 |
|
| 2023 |
Lu W, Fan M, Ji W, Tse J, You I, Ficarro SB, Tavares I, Che J, Kim AY, Zhu X, Boghossian A, Rees MG, Ronan MM, Roth JA, Hinshaw SM, ... ... Kwiatkowski N, et al. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors. Journal of Medicinal Chemistry. PMID 36946421 DOI: 10.1021/acs.jmedchem.2c01548 |
0.379 |
|
| 2023 |
Bohmer MJ, Wang J, Istvan ES, Luth MR, Collins JE, Huttlin EL, Wang L, Mittal N, Hao M, Kwiatkowski NP, Gygi SP, Chakrabarti R, Deng X, Goldberg DE, Winzeler EA, et al. Human Polo-like Kinase Inhibitors as Antiplasmodials. Acs Infectious Diseases. PMID 36919909 DOI: 10.1021/acsinfecdis.3c00025 |
0.444 |
|
| 2023 |
Yao Y, Fong Ng J, Park WD, Samur MK, Morelli E, Encinas J, Chyra Z, Xu Y, Derebail S, Epstein CB, Nabet B, Chesi M, Gray NS, Young R, Kwiatkowski N, et al. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. PMID 36877894 DOI: 10.1182/blood.2022018885 |
0.408 |
|
| 2022 |
Fan M, Lu W, Che J, Kwiatkowski NP, Gao Y, Seo HS, Ficarro SB, Gokhale PC, Liu Y, Geffken EA, Lakhani J, Song K, Kuljanin M, Ji W, Jiang J, et al. Covalent disruptor of YAP-TEAD association suppresses defective hippo signaling. Elife. 11. PMID 36300789 DOI: 10.7554/eLife.78810 |
0.456 |
|
| 2022 |
Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, Zhang T, Gray NS, Gustafson C, Krajewska M, George RE. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Frontiers in Oncology. 11: 773186. PMID 35198433 DOI: 10.3389/fonc.2021.773186 |
0.484 |
|
| 2022 |
Son J, Jang J, Beyett TS, Eum Y, Haikala HM, Verano A, Lin M, Hatcher JM, Kwiatkowski NP, Eser PÖ, Poitras MJ, Wang S, Xu M, Gokhale PC, Cameron MD, et al. A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. Cancer Research. PMID 35149586 DOI: 10.1158/0008-5472.CAN-21-2693 |
0.32 |
|
| 2022 |
Ryu S, Park JE, Ham YJ, Lim DC, Kwiatkowski NP, Kim DH, Bhunia D, Kim ND, Yaffe MB, Son W, Kim N, Choi TI, Swain P, Kim CH, Lee JY, et al. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. Journal of Medicinal Chemistry. PMID 35029981 DOI: 10.1021/acs.jmedchem.1c01359 |
0.373 |
|
| 2021 |
Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nature Reviews. Cancer. 22: 5-24. PMID 34675395 DOI: 10.1038/s41568-021-00411-8 |
0.405 |
|
| 2021 |
Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, et al. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry. 221: 113481. PMID 33945934 DOI: 10.1016/j.ejmech.2021.113481 |
0.461 |
|
| 2021 |
Jiang B, Gao Y, Che J, Lu W, Kaltheuner IH, Dries R, Kalocsay M, Berberich MJ, Jiang J, You I, Kwiatkowski N, Riching KM, Daniels DL, Sorger PK, Geyer M, et al. Discovery and resistance mechanism of a selective CDK12 degrader. Nature Chemical Biology. PMID 33753926 DOI: 10.1038/s41589-021-00765-y |
0.47 |
|
| 2021 |
Shirasaki R, Matthews GM, Gandolfi S, de Matos Simoes R, Buckley DL, Raja Vora J, Sievers QL, Brüggenthies JB, Dashevsky O, Poarch H, Tang H, Bariteau MA, Sheffer M, Hu Y, Downey-Kopyscinski SL, ... ... Kwiatkowski NP, et al. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports. 34: 108532. PMID 33406420 DOI: 10.1016/j.celrep.2020.108532 |
0.333 |
|
| 2020 |
Fan Z, Devlin JR, Hogg SJ, Doyle MA, Harrison PF, Todorovski I, Cluse LA, Knight DA, Sandow JJ, Gregory G, Fox A, Beilharz TH, Kwiatkowski N, Scott NE, Vidakovic AT, et al. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Science Advances. 6. PMID 32917631 DOI: 10.1126/Sciadv.Aaz5041 |
0.493 |
|
| 2020 |
Liu Y, Hao M, Leggett A, Gao Y, Ficarro SB, Che J, He Z, Olson C, Marto JA, Kwiatkowski N, Zhang T, Gray NS. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry. PMID 32502343 DOI: 10.1021/Acs.Jmedchem.9B01929 |
0.451 |
|
| 2020 |
Gray NS, Teng M, Jiang J, He Z, Kwiatkowski NP, Donovan KA, Mills CE, Victor C, Hatcher JM, Fischer ES, Sorger PK, Zhang T. Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angewandte Chemie (International Ed. in English). PMID 32415712 DOI: 10.1002/Anie.202004087 |
0.533 |
|
| 2020 |
Sivakumaren SC, Shim H, Zhang T, Ferguson FM, Lundquist MR, Browne CM, Seo HS, Paddock MN, Manz TD, Jiang B, Hao MF, Krishnan P, Wang DG, Yang TJ, Kwiatkowski NP, et al. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chemical Biology. PMID 32130941 DOI: 10.1016/J.Chembiol.2020.02.003 |
0.485 |
|
| 2019 |
Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, Li F, Pan Y, Zhang X, Yin Y, Papadopoulos E, Pyon V, Thakurdin C, Kwiatkowski N, Jani K, et al. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell. PMID 31883968 DOI: 10.1016/J.Ccell.2019.11.003 |
0.471 |
|
| 2019 |
Lian W, Jang J, Potisopon S, Li PC, Rahmeh A, Wang J, Kwiatkowski NP, Gray NS, Yang PL. Correction to Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. Acs Infectious Diseases. PMID 31675213 DOI: 10.1021/Acsinfecdis.9B00401 |
0.319 |
|
| 2019 |
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, ... ... Kwiatkowski NP, et al. A kinase-independent role for CDK8 in BCR-ABL1 leukemia. Nature Communications. 10: 4741. PMID 31628323 DOI: 10.1038/S41467-019-12656-X |
0.537 |
|
| 2019 |
Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nature Communications. 10: 1757. PMID 30988284 DOI: 10.1038/S41467-019-09703-Y |
0.457 |
|
| 2019 |
Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, ... ... Kwiatkowski N, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology. PMID 30905681 DOI: 10.1016/J.Chembiol.2019.02.012 |
0.573 |
|
| 2019 |
Pitts J, Hsia CY, Lian W, Wang J, Pfeil MP, Kwiatkowski N, Li Z, Jang J, Gray NS, Yang PL. Identification of small molecule inhibitors targeting the Zika virus envelope protein. Antiviral Research. PMID 30771406 DOI: 10.1016/J.Antiviral.2019.02.008 |
0.339 |
|
| 2019 |
De Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews G, Yiguo H, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Dempster J, Meyers RM, Bryan J, McFarland JM, Brueggenthies J, Tang H, ... ... Kwiatkowski NP, et al. Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma Blood. 134: 4407-4407. DOI: 10.1182/Blood-2019-130901 |
0.434 |
|
| 2019 |
Shirasaki R, Gandolfi S, De Matos Simoes R, Matthews GM, Buckley D, Raja J, Sievers QL, Dashevsky O, Poarch H, Tang H, Bariteau M, Sheffer M, Downey-Kopyscinski SL, Hengeveld P, Glassner B, ... ... Kwiatkowski NP, et al. Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins Blood. 134: 318-318. DOI: 10.1182/Blood-2019-130549 |
0.383 |
|
| 2018 |
Brand M, Jiang B, Bauer S, Donovan KA, Liang Y, Wang ES, Nowak RP, Yuan JC, Zhang T, Kwiatkowski N, Müller AC, Fischer ES, Gray NS, Winter GE. Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. Cell Chemical Biology. PMID 30595531 DOI: 10.1016/J.Chembiol.2018.11.006 |
0.448 |
|
| 2018 |
Browne CM, Jiang B, Ficarro SB, Doctor ZM, Johnson JL, Card JD, Sivakumaren SC, Alexander WM, Yaron T, Murphy CJ, Kwiatkowski NP, Zhang T, Cantley LC, Gray NS, Marto JA. A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification. Journal of the American Chemical Society. PMID 30518210 DOI: 10.1021/Jacs.8B07911 |
0.467 |
|
| 2018 |
Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 7. PMID 30422115 DOI: 10.7554/Elife.39030 |
0.51 |
|
| 2018 |
Lian W, Jang J, Potisopon S, Li PC, Rahmeh A, Wang J, Kwiatkowski NP, Gray NS, Yang PL. Discovery of Immunologically Inspired Small Molecules that Target the Viral Envelope Protein. Acs Infectious Diseases. PMID 30027735 DOI: 10.1021/Acsinfecdis.8B00127 |
0.355 |
|
| 2018 |
Hatcher JM, Wang ES, Johannessen L, Kwiatkowski N, Sim T, Gray NS. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. Acs Medicinal Chemistry Letters. 9: 540-545. PMID 29937979 DOI: 10.1021/Acsmedchemlett.8B00011 |
0.393 |
|
| 2018 |
Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology. PMID 29507391 DOI: 10.1038/S41589-018-0010-Y |
0.429 |
|
| 2018 |
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, ... Kwiatkowski N, et al. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 33: 173-186.e5. PMID 29438694 DOI: 10.1016/J.Ccell.2018.01.004 |
0.315 |
|
| 2018 |
Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, Zhang T, Wong KK, Gray NS, Young RA, Tsao H. High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma. The Journal of Investigative Dermatology. PMID 29408204 DOI: 10.1016/J.Jid.2017.09.056 |
0.491 |
|
| 2018 |
Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D, Benes CH, Young RA, et al. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell. PMID 29358035 DOI: 10.1016/J.Ccell.2017.12.009 |
0.537 |
|
| 2018 |
Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, et al. Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 Elife. DOI: 10.7554/Elife.39030.023 |
0.447 |
|
| 2018 |
Shirasaki R, Gandolfi S, De Matos Simoes R, Matthews G, Buckley D, Dashevsky O, Downey-Kopyscinski SL, Tang H, Sheffer M, Dhimolea E, Glassner B, Bariteau M, Sorrell J, Bruggenthies JB, Sievers Q, ... ... Kwiatkowski NP, et al. CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias Blood. 132: 1367-1367. DOI: 10.1182/Blood-2018-99-116232 |
0.42 |
|
| 2018 |
Shirasaki R, Gandolfi S, Simoes RDM, Matthews G, Downey S, Dashevsky O, Huihui T, Sheffer M, Dhimolea E, Bariteau M, Sorrel J, Kwiatkowski N, Zhang T, Gray N, Mitsiades C. Abstract 2834: Genomewide CRISPR studies of sequential treatment with CRBN-based degronimids: Insights into the molecular evolution of treatment resistance in myeloma and beyond Cancer Research. 78: 2834-2834. DOI: 10.1158/1538-7445.Am2018-2834 |
0.454 |
|
| 2017 |
Gao Y, Zhang T, Terai H, Ficarro SB, Kwiatkowski N, Hao MF, Sharma B, Christensen CL, Chipumuro E, Wong KK, Marto JA, Hammerman PS, Gray NS, George RE. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chemical Biology. PMID 29276047 DOI: 10.1016/J.Chembiol.2017.11.007 |
0.457 |
|
| 2017 |
Terai H, Kitajima S, Potter DS, Matsui Y, Gutierrez Quiceno L, Chen T, Kim TJ, Rusan M, Thai TC, Piccioni F, Donovan KA, Kwiatkowski N, Hinohara K, Wei G, Gray NS, et al. ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors. Cancer Research. PMID 29259014 DOI: 10.1158/0008-5472.Can-17-1904 |
0.487 |
|
| 2017 |
Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, Zhang T, Kwiatkowski N, Boukhali M, Green JL, Haas W, Nomanbhoy T, Fischer ES, Young RA, Bradner JE, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology. PMID 29251720 DOI: 10.1038/Nchembio.2538 |
0.552 |
|
| 2017 |
Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discovery. PMID 29054992 DOI: 10.1158/2159-8290.Cd-17-0461 |
0.482 |
|
| 2017 |
Kalan S, Amat R, Schachter MM, Kwiatkowski N, Abraham BJ, Liang Y, Zhang T, Olson CM, Larochelle S, Young RA, Gray NS, Fisher RP. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Reports. 21: 467-481. PMID 29020632 DOI: 10.1016/J.Celrep.2017.09.056 |
0.541 |
|
| 2017 |
Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature Communications. 8: 14747. PMID 28218232 DOI: 10.1038/Ncomms14747 |
0.37 |
|
| 2017 |
Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, Weichert-Leahey N, Rahman S, Liu Y, Etchin J, Li B, Shen S, Lee TI, Zhang J, Look AT, et al. Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications. 8: 14385. PMID 28181482 DOI: 10.1038/Ncomms14385 |
0.313 |
|
| 2017 |
Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature Communications. 8: 14290. PMID 28134252 DOI: 10.1038/Ncomms14290 |
0.5 |
|
| 2017 |
Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski K, Bockorny B, Chen T, Li S, Zhang H, Terai H, Tavares T, Zhang T, Kim TJ, et al. Abstract 15: Suppression of adaptive responses to targeted therapies by transcriptional inhibition Cancer Research. 77: 15-15. DOI: 10.1158/1538-7445.Am2017-15 |
0.383 |
|
| 2017 |
Balboni AL, Stolte B, Conway AS, Alexe G, Wang EJ, Kwiatkowski N, Zhang T, Abraham BJ, Kalev P, Chowdhury D, Benes CH, Young RA, Gray NS, Stegmaier K. Abstract 1118: Synthetic lethality of CDK12 inhibition in tumors with EWS/FLI rearrangements Cancer Research. 77: 1118-1118. DOI: 10.1158/1538-7445.Am2017-1118 |
0.547 |
|
| 2016 |
Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology. PMID 27571479 DOI: 10.1038/Nchembio.2166 |
0.561 |
|
| 2016 |
Krajewska M, Moore NF, Chipumuro E, Zhang T, Marco E, Hatheway C, Sharma B, Kwiatkowski N, Yuan G, Young RA, Gray NS, George RE. Abstract PR04: Targeting super-enhancer driven oncogene transcription through cyclin-dependent kinase inhibitors Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-Pr04 |
0.549 |
|
| 2016 |
Balboni A, Stolte B, Kalev P, Kwiatkowski N, Zhang T, Abraham B, Alexe G, Chowdhury D, Young RA, Gray NS, Stegmaier K. Abstract 2441: CDK12/13 inhibition cooperates with the Ewing sarcoma oncoprotein EWS/FLI to attenuate homologous recombination repair in Ewing sarcoma cells Cancer Research. 76: 2441-2441. DOI: 10.1158/1538-7445.Am2016-2441 |
0.553 |
|
| 2016 |
Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Rahman S, Li Z, Lee TI, Look AT, Mansour M, Young RA. Abstract 2004: Nucleation of transcriptional super-enhancers at tumor oncogenes by small insertions Cancer Research. 76: 2004-2004. DOI: 10.1158/1538-7445.Am2016-2004 |
0.404 |
|
| 2015 |
Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, et al. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell. 163: 174-186. PMID 26406377 DOI: 10.1016/J.Cell.2015.08.063 |
0.473 |
|
| 2015 |
Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Molecular Oncology. 9: 260-9. PMID 25226813 DOI: 10.1016/J.Molonc.2014.08.011 |
0.456 |
|
| 2015 |
Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong K, Yuan G, Gray NS, Young RA, et al. Abstract PR05: Targeting of CDK7 inhibits super-enhancer-associated oncogenic programs in MYCN-amplified tumor cells Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr05 |
0.519 |
|
| 2015 |
Abraham BJ, Kwiatkowski N, Weintraub AS, Hnisz D, Hannett N, Young RA. Abstract PR14: Nucleation of transcriptional super-enhancers at tumor oncogenes Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr14 |
0.4 |
|
| 2015 |
Abraham BJ, Kwiatkowski N, Weintraub AS, Hnisz D, Hannett N, Young RA. Abstract PR06: Nucleation of transcriptional super-enhancers at tumor oncogenes Cancer Research. 75. DOI: 10.1158/1538-7445.Compsysbio-Pr06 |
0.4 |
|
| 2015 |
Christensen C, Kwiatkowski N, Abraham B, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie G, Akbay E, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel J, Cavanaugh J, et al. Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor Cancer Cell. 27: 149. DOI: 10.1016/J.Ccell.2014.12.007 |
0.469 |
|
| 2014 |
Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 26: 909-22. PMID 25490451 DOI: 10.1016/J.Ccell.2014.10.019 |
0.523 |
|
| 2014 |
Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, Gray NS, Young RA, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 159: 1126-39. PMID 25416950 DOI: 10.1016/J.Cell.2014.10.024 |
0.534 |
|
| 2014 |
Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 511: 616-20. PMID 25043025 DOI: 10.1038/Nature13393 |
0.549 |
|
| 2014 |
Praditsuktavorn P, Pera B, Kwiatkowski N, Yang S, Zhang T, Gray N, Cerchietti L. Transcription Regulation Targeting in Peripheral T Cell Lymphomas Induces Apoptosis and Sensitization to BCL2 Inhibitors Blood. 124: 810-810. DOI: 10.1182/Blood.V124.21.810.810 |
0.529 |
|
| 2014 |
Chipumuro E, Marco E, Zhang T, Christensen C, Kwiatkowski N, Sharma B, Hatheway C, Altabef A, Abraham BJ, Wong K, Yuan G, Young RA, Gray NS, George RE. Abstract LB-125: Selective inhibition of CDK7 targets MYCN-driven transcriptional amplification in neuroblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-125 |
0.556 |
|
| 2013 |
Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. Journal of the National Cancer Institute. 105: 1322-31. PMID 23940287 DOI: 10.1093/Jnci/Djt168 |
0.419 |
|
| 2013 |
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702 |
0.496 |
|
| 2012 |
Zhang Z, Kwiatkowski N, Zeng H, Lim SM, Gray NS, Zhang W, Yang PL. Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy. Molecular Biosystems. 8: 2523-6. PMID 22673640 DOI: 10.1039/C2Mb25099C |
0.374 |
|
| 2012 |
Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, Gray N. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. Acs Chemical Biology. 7: 185-96. PMID 21992004 DOI: 10.1021/Cb200305U |
0.52 |
|
| 2011 |
Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, Gray NS. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chemistry & Biology. 18: 868-79. PMID 21802008 DOI: 10.1016/J.Chembiol.2011.05.010 |
0.459 |
|
| 2011 |
Deng X, Yang Q, Kwiatkowski N, Sim T, McDermott U, Settleman JE, Lee JD, Gray NS. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. Acs Medicinal Chemistry Letters. 2: 195-200. PMID 21412406 DOI: 10.1021/Ml100304B |
0.42 |
|
| 2011 |
Sansregret L, Vadnais C, Livingstone J, Kwiatkowski N, Awan A, Cadieux C, Leduy L, Hallett MT, Nepveu A. Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure. Proceedings of the National Academy of Sciences of the United States of America. 108: 1949-54. PMID 21245318 DOI: 10.1073/Pnas.1008403108 |
0.391 |
|
| 2010 |
Jelluma N, Dansen TB, Sliedrecht T, Kwiatkowski NP, Kops GJ. Release of Mps1 from kinetochores is crucial for timely anaphase onset. The Journal of Cell Biology. 191: 281-90. PMID 20937696 DOI: 10.1083/Jcb.201003038 |
0.306 |
|
| 2010 |
Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America. 107: 12617-22. PMID 20616024 DOI: 10.1073/Pnas.1006774107 |
0.425 |
|
| 2010 |
Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, Gray NS. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nature Chemical Biology. 6: 359-68. PMID 20383151 DOI: 10.1038/Nchembio.345 |
0.51 |
|
| 2008 |
Estiu G, Greenberg E, Harrison CB, Kwiatkowski NP, Mazitschek R, Bradner JE, Wiest O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. Journal of Medicinal Chemistry. 51: 2898-906. PMID 18412327 DOI: 10.1021/Jm7015254 |
0.402 |
|
| 2008 |
Andersen CB, Wan Y, Chang JW, Riggs B, Lee C, Liu Y, Sessa F, Villa F, Kwiatkowski N, Suzuki M, Nallan L, Heald R, Musacchio A, Gray NS. Discovery of selective aminothiazole aurora kinase inhibitors. Acs Chemical Biology. 3: 180-92. PMID 18307303 DOI: 10.1021/Cb700200W |
0.447 |
|
| 2008 |
Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. The Journal of Biological Chemistry. 283: 11355-63. PMID 18285338 DOI: 10.1074/Jbc.M707362200 |
0.381 |
|
| Show low-probability matches. |